Zelnorm Surgery Incidence Halved Via Novartis/FDA Adjudication
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Re-analysis of surgical cases in clinical trials for Novartis’ constipation-predominant irritable bowel syndrome therapy Zelnorm reduced the incidence of the events by more than half, FDA review documents indicate.